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Chapter 10 
Therapeutic Evolution or Revolution? Metaphors and Their Consequences 
David S. Jones 
 When Cleveland surgeon René Favaloro published his description of coronary artery 
bypass grafting in 1968, he launched one of the most important surgical procedures in the United 
States.1 Speaking at a conference in Houston in 1985, he described 1968 as the “year of 
revolution.”2 When interviewed a decade later, however, Favaloro used a different metaphor. As 
he described it, “The evolution took place in just a few months from patch graft to interposition 
graft to bypass graft.”3 So which was it: an evolution or a revolution? Debates about the 
meanings and merits of these two metaphors for historical change have been a fixture of the 
historiography of science and medicine for decades. Although historians do not argue as much 
about whether or not a particular development counted as a “scientific revolution” as they did 
when Thomas Kuhn’s Structure of Scientific Revolutions was fresh, the choice of “evolution” or 
“revolution” remains important, especially in the history of medicine and therapeutics. The two 
metaphors carry very different connotations for our understandings of how and why medical 
practice changes over time. 
 Revolutions, as the essays in this volume make clear, receive the lion’s share of attention 
from historians. Charles Rosenberg’s classic essay on the “therapeutic revolution,” revisited at 
                                            
1 René G. Favaloro, “Saphenous Vein Autograft Replacement of Severe Segmental Coronary 
Artery Occlusion,” Annals of Thoracic Surgery 5 (1968): 334-339. 
2 Favoloro, quoted in THI Today (December 1985), p. 2, in John P. McGovern Historical 
Collections and Research Center (Houston Academy of Medicine), Institutional Collection #43 
(Texas Heart Institute), Box 2, Folder “THI Today, 1985”. 
3 Favaloro, “Oral History” (3 March 1997), in Pioneers of Cardiac Surgery, ed. William S. 
Stoney (Nashville: Vanderbilt University Press, 2008), pp. 357-368, on p. 364. 
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the end of this volume, has set the standard for therapeutic history for nearly forty years.4 Yet 
Rosenberg’s 1977 essay principally focused on a nosological revolution that only secondarily 
transformed therapeutics. Others have written about the bacteriological revolution, the antibiotic 
revolution that followed, and the broader pharmaceutical revolution in the 1950s. Geneticists 
have for decades been making promissory claims about a genetic revolution that will introduce a 
new epoch of personalized, precision medicine.5 Historians of surgery have described the 
anesthetic and aseptic revolutions. One cardiologist, channeling Kuhn, has even described “The 
Structure of Cardiological Revolutions.”6 
 Evolution, however, is also ubiquitous in the medical literature. Consider the field of 
cardiology, once named “the youngest child of medical evolution.”7 Atherosclerotic plaques 
undergo “evolution,”8 as do cardiac surgery procedures,9 anesthetic techniques,10 and the 
                                            
4 Charles Rosenberg, “The Therapeutic Revolution: Medicine, Meaning, and Social Change in 
Nineteenth-Century America,” Perspectives in Biology and Medicine 20 (1977): 485-506. 
5 David S. Jones, “The Prospects of Personalized Medicine,” in Genetic Explanation: Sense and 
Nonsense, ed. Sheldon Krimsky and Jeremy Gruber (Cambridge: Cambridge: Harvard University 
Press, 2013), pp. 147-170; Reza Mirnezami, Jeremy Nicholson, and Ara Darzi, “Preparing for 
Precision Medicine,” New England Journal of Medicine 366 (2012): 489-491. 
6 Burton E. Sobel, “The Structure of Cardiological Revolutions,” Circulation 87 (1993): 2047-
2054. Sobel described three revolutions: a “social revolution” that led to declining prestige of the 
profession, the revolution of interventional cardiology, and the revolution of molecular and 
cellular biology. 
7 Louis Faugères Bishop and John Neilson, History of Cardiology (New York: Medical Life 
Press, 1927), 71. 
8 Peter Libby, Paul M. Ridker, and Attilio Maseri, “Inflammation and Atherosclerosis,” 
Circulation 105 (2002): 1135-1143. 
9 Floyd D. Loop, Delos M. Cosgrove, Bruce W. Lytle, Robert L. Thurer, Conrad Simpfendorfer, 
Paul C. Taylor, and William L. Proudfit, “An 11-Year Evolution of Coronary Arterial Surgery,” 
Annals of Surgery 190 (October 1979): 444-454. 
10 A.S. Keats, “Evolution of Anesthesia for Cardiac Surgery,” Cleveland Clinic Quarterly 48 
(1981): 75-79. 
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specialties of cardiology and cardiac surgery.11 Doctors can use electrocardiograms to follow a 
heart attack’s “electrocardiographic evolution.”12 New operations and instruments have been 
evolved.13 When cardiac surgeons began to face competition from the new field of interventional 
cardiology, many realized that “only our ability to evolve will guarantee our survival.”14 Even 
patients joined the effort: “Patients undergoing coronary bypass grafting have undergone an 
evolution in recent years.”15 At times physicians have explicitly debated which metaphor -- 
evolution or revolution -- offers the more apt description for whatever therapeutic changes 
happen to interest them, whether heart-lung machines, statin therapy, or endovascular repair of 
abdominal aortic aneurysms.16 A revolution itself, such as that produced by transesophageal 
echocardiography, can undergo evolution.17 
 The language of evolution has been entrenched in the history of medicine as well. In 
April 1913, for instance, William Osler gave lectures at Yale titled the “Evolution of Medicine.” 
                                            
11 Ellis J. Jones, William S. Weintraub, Joseph M. Carver, Robert A. Guyton, and Caryn L. 
Cohen, “Coronary Bypass Surgery: Is the Operation Different Today,” Journal of Thoracic and 
Cardiovascular Surgery 101 (1991): 108-115. 
12 Anthony P. Fletcher, Sol Sherry, Norma Alkjaersig, Fotios E. Smyrniotis, and Sidney Jick, 
“The Maintenance of a Sustained Thrombolytic State in Man,” Journal of Clinical Investigation 
38 (1959): 1111-1119. 
13 Michael E. DeBakey, “Changing Concepts in Thoracic and Vascular Surgery,” Journal of 
Thoracic and Cardiovascular Surgery 38 (1959): 145-165. 
14 Michael Mack, Ralph Damiano, Robert Matheny, Hermann Reichenspurner and Alain 
Carpentier, “Inertia of Success: A Response to Minimally Invasive Coronary Bypass: A 
Dissenting Opinion,” Circulation 99 (1999): 1404-1406. 
15 Jones and others, “Coronary Bypass Surgery.” 
16 F. Trojette, A. Benamar, S. Beloucif, D. Foure, H.J. Poulain, “Clinical Experience with the 
Mini-extracorporeal Circulation System: An Evolution or a Revolution?” Annals of Thoracic 
Surgery 77 (2004): 2172-2176; P. Rehfield, C. Kopes-Kerr, and M. Clearfield, “The Evolution or 
Revolution of Statin Therapy in Primary Prevention: Where Do We Go from Here?” Current 
Atherosclerosis Reports 15 (2013): 298; C. Lee, C.S. Barroso, and P.J. Troped, “Endovascular 
Aneurysm Sealing for Abdominal Aortic Aneurysm Repair: Evolution or Revolution?” 
Cardiovascular and Interventional Radiology 37 (October 2014): 1129-1136. 
17 J.R.T.C. Roelandt, I.R. Thomson, W.B. Vletter, P. Brommersma, N. Bom, D.T. Linker, 
“Multiplane Transesophageal Echocardiography: Latest Evolution in an Imaging Revolution,” 
Journal of the American Society of Echocardiography 5 (1992): 361-367. 
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He sought to tell the story of medical progress. Even though the path might not have been linear, 
medical theory and practice improved with evolution: “like a living organism, truth grows, and 
its gradual evolution may be traced from the tiny germ to the mature product. Never springing, 
Minerva-like, to full stature at once, truth may suffer all the hazards incident to generation and 
gestation.”18 As the editors describe in their introduction to this volume, Fielding Garrison 
praised Osler’s “panoramic survey” of the painful evolution of medicine from superstition to 
rationality. Garrison hoped that Osler’s narrative of evolutionary progress would be an 
inspiration to students and other readers.19 
 Even though historians of medicine have since learned to be skeptical of positivism and 
Whiggish “just-so” stories, evolution remains widespread in historians’ writing. Historians have 
published essays on the evolution of medical ideas, for instance of the term “chancre,” of 
Darwin’s concept of pangenesis, of clinical trials, or of Harvey Cushing’s thoughts about 
specialization.20 They have traced the evolution of medical techniques, including endotracheal 
anesthesia, prophylactic enucleation of the eye, bronchial casts, or frozen sections (and the 
impact of those on the evolution of surgical pathology).21 And they have narrated the evolution 
                                            
18 William Osler, The Evolution of Medicine (New Haven: Yale University Press, 1922), 219. 
19 Field H. Garrison, “Preface,” in Osler, The Evolution of Medicine, xiii. 
20 Harry Keil, “The Evolution of the Term Chancre and Its Relation to the History of Syphilis,” 
Journal of the History of Medicine and Allied Sciences 4 (1949): 407-416; Gerald L. Geison, 
“Darwin and Heredity: The Evolution of His Hypothesis of Pangenesis,” Journal of the History 
of Medicine and Allied Sciences 4 (1969): 375-411; Abraham M. Lilienfeld, “Ceteris Paribus: 
The Evolution of the Clinical Trial,” Bulletin of the History of Medicine 56 (1982): 1-18; Samuel 
H. Greenblatt, “Harvey Cushing’s Paradigmatic Contribution to Neurosurgery and the Evolution 
of His Thoughts about Specialization,” Bulletin of the History of Medicine 77 (2003): 789-822. 
21 Noel Gillespie, “The Evolution of Endotracheal Anaesthesia,” Journal of the History of 
Medicine and Allied Sciences 1 (1946): 583-594; R.K. Blach, “Prophylactic Enucleation in 
Sympathetic Ophthalmitis: The Evolution of an Heroic Form of Treatment,” Medical History 15 
(1971): 190-192; Andrew Davies, “The Evolution of Bronchial Casts,” Medical History 17 
(1973): 386-391; James R. Wright, “The Development of the Frozen Section Technique, the 
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of medical institutions, from the Mayo Clinic to health services in India.22 Such articles rarely 
invoke anything more than the most superficial idea of evolution as a process of gradual, 
progressive change over time.23 
 What are we to make of the co-existence of evolution and revolution in medicine and its 
histories? Both words are often used casually in English, without careful attention to their 
specific meanings or connotations. The meanings of “evolution” have themselves evolved over 
time, and many discordant meanings remain in use today.24 From the Latin evolver, to rollout or 
unroll (as in unrolling a scroll), evolution first appeared in English in the mid-seventeenth 
century. It was used in different ways, to describe the wheeling movement of dancers, the course 
of childbirth, or the working out of God’s plan for creation. By the eighteenth century it 
increasingly implied a gradual change in a system from a simpler to a more complex state, as in 
embryological development. This meaning generalized in biology to describe the transformation 
of organisms over time. “Revolution,” as described elsewhere in this book, has followed an 
equally complex course, from a revolving movement in space or time, to violent upheaval and 
                                                                                                                                             
Evolution of Surgical Biopsy, and the Origins of Surgical Pathology,” Bulletin of the History of 
Medicine 59 (1985): 295-326. 
22 H.P. Tait, “Health Services in India and Burma: Their Evolution and Present Status, Medical 
History 16 (1972): 184-193; W. Bruce Fye, “The Origins and Evolution of the Mayo Clinic from 
1864 to 1939: A Minnesota Family Practice Becomes an International ‘Medical Mecca,’” 
Bulletin of the History of Medicine 84 (2010): 323-357. 
23 One essay, for instance, on the evolution of the concept of febrile seizures, describes how 
“Beginning in the mid-nineteenth century and continuing as a gradual process to the present, this 
thinking has changed dramatically.” See John W. Gardner and Robert C. Dinsmore, “Evolution 
of the Concept of the Febrile Seizure as It Developed in the American Medical Literature, 1800-
1980,” Journal of the History of Medicine and Allied Sciences 50 (1995): 340-363, on p. 341. 
24 “Evolution,” Oxford English Dictionary, 3rd edition (March 2008), available at 
www.oed.com; Raymond Williams, “Evolution,” in Keywords: A Vocabulary of Culture and 
Society, revised edition (New York: Oxford University Press, 1983), 120-123; Robert J. 
Richards, “Evolution,” in Keywords in Evolutionary Biology, eds. Keller and Elisabeth A. Lloyd 
(Cambridge: Harvard University Press, 1992), 95-105, on p. 95; Richard C. Lewontin, 
“Organism and Environment,” in Learning, Development, and Culture, ed. H.C. Plotkin (New 
York: John Wiley & Sons Ltd., 1982), pp. 151-170, especially 152-156. 
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the overthrow of an established social or political order.25 By the nineteenth century the sudden 
overthrow of revolution was contrasted against the gradual, organic reforms of evolution.26 But 
this distinction was never perfect, with evolution in biology including ruthless struggles between 
species and dramatic extinctions. Do doctors and historians actually intend any of these specific 
meanings when they use “revolution” or “evolution” in their writing? Cardiological revolutions 
do not involve violent overthrow, and the evolution of cardiac surgery does not rely on surgeons’ 
differential reproductive success. 
 There is meaning in the words nonetheless. Evolution and revolution are both models of 
change over time. It is easy to see the appeal of a claim of revolution for scientists, and for their 
historians: it pronounces a radical break from the past, confident and triumphant. Progress is 
implied by the decisiveness of the rupture. Such rhetoric is good for marketing, especially when 
contrasted against the cautious gradualism of evolution. But evolution has its own appeals, 
especially its reassuring connotations of progressive improvement. Roy Porter defined the stakes 
well in his 1986 essay on scientific revolutions.27 He described the juxtaposition of evolution and 
revolution as a contrast between continuity and cataclysm. He argued that if historians would not 
stake a claim about this distinction, they put themselves “in danger of defaulting on the task of 
assessing overall patterns of science.”28 However, they had to proceed with caution. Porter 
advocated a narrow definition of scientific revolutions: they ought to involve a self-conscious 
                                            
25 “Revolution,” Oxford English Dictionary, 3rd edition (March 2010), available at 
www.oed.com; Raymond Williams, “Revolution,” in Keywords, 270-274. 
26 Williams, “Evolution,” 122; Williams, “Revolution,” 273. 
27 Roy Porter, “The Scientific Revolution: A Spoke in the Wheel?” in Revolution in History, ed. 
Porter and Mikuláš Teich (Cambridge: Cambridge University Press, 1986), 290-316. 
28 Porter, “The Scientific Revolution,” 300. He writes: “is it helpful to picture the course of the 
history of science as revolutionary? Or might it not make better sense to stress its ‘evolutionary’ 
aspects, its continuities and accommodation to the wider socio-intellectual environment? These 
large questions matter, not least because, with the irresistible rise of specialization, scholarship 
becomes myopic and fragmented” (300). 
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process of challenge, resistance, and struggle, the deliberate “overthrow of an entrenched 
orthodoxy.”29 By this standard, the seventeenth century did bring some revolutionary changes to 
the sciences, but the changes in nineteenth century medical theory that Rosenberg described were 
merely a crisis, not a revolution.30 Even though he winnowed the list of scientific revolutions, 
Porter also warned against a “retreat into an evolutionary metaphor of science’s development, on 
some specious analogy with the dictum natura non facit saltum.”31 What he wanted was 
deliberate, thoughtful, discussions of the pace and character of scientific change. His demand 
remains relevant today. 
 It is not enough simply to debate what counts, or not, as revolution or evolution. Instead, 
much can be gained through serious engagement with the theory and language of revolution and 
evolution in pursuit of the best possible accounts of scientific change. Porter, and the other 
essays in this book, did this with revolution. Something similar can be done with evolution. 
Relevant concepts, and their components, can be made into meaningful guides for historical 
analysis. Evolutionary biologists have developed an elaborate theoretical apparatus to understand 
the processes of organismic evolution, with analyses of niches, fitness, competition, the Red 
Queen hypothesis, extinction, taxonomy, island biogeography, and morphospace. Some of these 
ideas, such as the niche, have already been adapted by historians. Other aspects can be adapted to 
history as well, an exercise that can be thought provoking and even productive. 
 It is, of course, important not to be cavalier when borrowing ideas across scholarly 
disciplines. Richard Lewontin, a noted evolutionary theorist, has warned scholars in other fields 
not to appropriate concepts of evolution, because evolutionary theory was developed to explain 
                                            
29 Porter, “The Scientific Revolution,” 300. 
30 Porter, “The Scientific Revolution,” 308. 
31 Porter, “The Scientific Revolution,” 309. 
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biological change, not social change, and its concepts cannot be casually applied across the latter 
domain.32 Scholars have long contested efforts to apply evolution to psychology, sociology, and 
social policy.33 Similar concerns exist with history. Applying biological theory to history risks 
naturalizing what are actually social, economic, and political processes. Moreover, theories of 
evolution, like those of revolution, carry connotations of progress. These can confound 
understandings of progress in medicine, something that has long been a vexing issue for 
historians. Used carefully, however, the language of evolution can be a valuable tool for 
historians to think with. 
 
Niche 
 In basic ecological and evolutionary theory, a niche is the space or role in an environment 
occupied by a particular species. Bees pollinate flowers, bats eat mosquitoes, and so forth. 
Historians of medicine have taken up the niche concept in two different ways. In Last Resort, 
Jack Pressman explained why lobotomy worked in the 1940s but not forty years later.34 He 
offered the niche as an intuitive, ecological metaphor. The efficacy of a treatment can only be 
understood in the context of the particular problem the treatment offers to solve: “the extent to 
which a treatment flourishes is directly dependent upon the specific features of the day’s clinical 
landscape. In the long haul, viability is a matter of ecology, not virtue.”35 In the 1930s, asylums 
overflowed with patients, hopelessness, and horror. Psychiatrists desperately sought new 
                                            
32 Richard Lewontin, Conversation with the Author, 23 May 2011. 
33 For one revealing exchange, see Stephen J. Gould, “Darwinian Fundamentalism,” New York 
Review of Books 44 (12 June 1997): 34–37; Steven Pinker, with a reply by Gould, 
“Evolutionary Psychology: An Exchange,” New York Review of Books 44 (9 October 1997). 
34 Jack Pressman, Last Resort: Psychosurgery and the Limits of Medicine (Cambridge: 
Cambridge University Press, 1998). 
35 Pressman, Last Resort, 14; see also p. 160. 
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treatments. Lobotomy, which could calm some patients (albeit at the cost of damaging their 
personality), offered “human salvage.” It appealed to patients, their families, and psychiatrists. 
Pressman’s metaphor was explicit: “from an ecological perspective, the treatment rapidly 
penetrated into a niche of almost limitless size that as yet had no competitors.”36 
 Ian Hacking used niche models to explain the history of dissociative fugues and other 
diseases that appear in a society only to vanish at some future date: “I argue that one fruitful idea 
for understanding transient mental illness is the ecological niche, not just social, not just medical, 
not just coming from the patient, not just from the doctors, but from the concatenation of an 
extraordinarily large number of diverse types of elements which for a moment provide a stable 
home for certain manifestations of illness.”37 He argued that four “vectors” defined the extent of 
the niche: medical taxonomy (or nosology), cultural polarity, observability, and release. As these 
vectors change over time, so do the niches, and the diseases themselves: “To postulate a niche 
for an illness is to make two kinds of claims, one positive, one negative. In the presence of the 
relevant vectors, the illness flourishes; in their absence it does not.”38 For both Pressman and 
Hacking, the metaphor of the niche provided an analytic framework that accounted for changing 
diseases and treatments over time. 
 While the niche concept has clear value, it introduces some risks. As Lewontin has 
warned, invocation of a biological concept like “niche” in a historical analysis might reify the 
phenomena being studied. This is a risk, since existing scholarship on changing diagnostic 
categories and therapeutic practices has shown that there is little natural about these dynamics. 
Historians have described many cases in which interested groups have, in effect, created niches 
                                            
36 Pressman, Last Resort, 190. 
37 Ian Hacking, Mad Travelers: Reflections on the Reality of Transient Mental Illness 
(Charlottesville, Va.: University of Virginia Press, 1998), 13. 
38 Hacking, Mad Travelers, 82. 
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for diseases or treatments. Patient activists have pushed diseases onto the medical agenda. 
Pharmaceutical executives have publicized diseases to create new markets for their products. 
When diuretics and tricyclic antidepressants appeared in the 1950s, Merck and other companies 
distributed educational materials to popularize the diseases -- hypertension and depression -- that 
the drugs could treat.39 This set the precedent for many diseases (and their drugs), from social 
anxiety disorder to restless leg syndrome and erectile dysfunction.40 
 Historians have often analyzed these cases an alternative metaphor, that of the market. 
While market analyses have obvious relevance and value, they focus on just one aspect of the 
phenomena -- money. Niche models offer a broader approach that can incorporate other 
dynamics. Moreover, the risk of naturalization can be minimized by emphasizing the social 
factors that define the niche. Pressman described overflowing asylums, psychiatrists in search for 
respect, and legislatures concerned by growing mental health budgets. Hacking’s vectors were 
intellectual and cultural, from medical theorizing about epilepsy to the new popularity of cycling. 
However, avoiding the biological baggage of niche can be tricky to do. Hacking, for instance, 
equivocates, suggesting that there had to be “an ecological niche in which the construction could 
thrive.”41 This just begs the question. 
 Tensions about whether a niche is natural or constructed are embedded deep in the 
origins of the word itself. “Niche” has been used since the eighteenth century to describe the lair 
                                            
39 David Healy, The Antidepressant Era (Cambridge: Harvard University Press, 1997); Jeremy 
A. Greene, Prescribing by Numbers: Drugs and the Definition of Disease (Baltimore: Johns 
Hopkins University Press, 2007). 
40 Ray Moynihan and David Healy, “The Fight Against Disease Mongering: Generating 
Knowledge for Action,” PLoS Medicine 3 (2006): e191. 
41 Hacking, Mad Travelers, 101. 
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of an animal or a suitable place for a person. This usage was borrowed from architecture.42 
“Niche” first appeared in English in 1610 to specify a space, often in cathedrals, built to house 
statues and relics; it replaced an older Latin term, aedicula, meaning a small house.43 The 
derivation of “niche” itself remains contested. Some trace the word to a French source, also 
niche, meaning a kennel for a dog, or possibly nichier, meaning to make a nest. Others prefer an 
Italian source, nicchio, for seashell.44 In either case, the architectural term “niche” has its roots, 
ironically, in nature. The ambiguity about whether a niche is natural or constructed simply 
recapitulates this etymology. 
 Recent developments in evolutionary theory offer a possible solution to this tension. 
When ecologists developed niche theories in the 1910s and the 1920s, they focused on 
characteristics of an organism’s environment (e.g., availability of food and shelter, competition 
and predation, etc.).45 In 1957, however, G. Evelyn Hutchinson re-conceptualized the niche as a 
property of the species in relation to its environment.46 This definition introduced the distinction 
between the fundamental niche (i.e., that which was possibly achievable by a species) and the 
realized niche. Meanings of “niche” shifted again in the 1970s when Richard Lewontin 
popularized the idea of “niche construction.”47 Beavers build dams, grazers alter the species 
                                            
42 James R. Griesemer, “Niche: Historical Perspectives,” in Keywords in Evolutionary Biology, 
230-240. Caroline Jones, at the Massachusetts Institute of Technology, alerted me to this history: 
Mark Jarzombek to Caroline Jones, 24 June 2009, email shared with author. 
43 “Niche,” Oxford English Dictionary, available at www.oed.com. For the evolution of aedicula 
in medieval cathedral architecture, see John Summerson, “Heavenly Mansions: An Interpretation 
of Gothic,” in Heavenly Mansions and other Essays on Architecture (London: Cresset Press, 
1949): 1-28. 
44 Online Etymology Dictionary, available at http://www.etymonline.com. 
45 Griesemer, “Niche.” 
46 Griesemer, “Niche,” 238-239; Robert K. Colwell, “Niche: A Bifurcation in the Conceptual 
Lineage of the Term,” in Keywords in Evolutionary Biology, 241-248. 
47 Richard Lewontin, “Adaptation,” Scientific American 239 (September 1978): 212-230, on p. 
215. See also: F. John Odling-Smee, Kevin N. Laland, Marcus W. Feldman, “Niche 
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compositions of fields where they graze, and trees create myriad niches around themselves. As 
Lewontin later explained, organisms “are not simply objects of the laws of nature, altering 
themselves to bend to the inevitable, but active subjects transforming nature according to its 
laws.”48 By shifting the focus from adaptation to construction, evolution becomes a coupled 
process in which organisms are functions of their environment and environments are functions of 
their organisms.49 
 Understood in light of these modern formulations, the niche becomes a productive model 
for historians of medicine. It has both ecological connotations, suggesting an opportunity within 
an environment, and architectural connotations, suggesting a built space (which can encompass 
market strategies). In the simplest application, a therapeutic niche might simply be a disease or 
symptom in need of treatment. The rise of coronary artery disease in the twentieth century, for 
instance, opened a niche for a diverse assortment of pharmaceutical and surgical treatments. But 
the niche is not simply a phenomenon of the physical disease environment; the niche is also a 
social process. It might be the recognition of the need to manage some aspect of the burden of 
                                                                                                                                             
Construction,” American Naturalist 147 (1996): 641-648. As they explain, “The idea here, in 
retrospect, is obvious: “Organisms, through their metabolism, their activities, and their choices, 
define, partly create, and partly destroy their own niches” (641). 
48 Richard C. Lewontin, “Organism and Environment,” in Learning, Development, and Culture, 
ed. H.C. Plotkin (New York: John Wiley & Sons Ltd., 1982), 151-170, on p. 163. 
49 Richard Lewontin, “Gene, Organism, Environment,” in Evolution from Molecules to Men, ed. 
D.S. Bendall (Cambridge: Cambridge University Press, 1983), 273-285; Clive G. Jones, John H. 
Lawton, and Moshe Shachak, “Positive and Negative Effects of Organisms as Physical 
Ecosystem Engineers,” Ecology 78 (1997): 1946-1957; F. John Odling-Smee, Kevin N. Laland, 
Marcus W. Feldman, “Niche Construction,” American Naturalist 147 (1996): 641-648; K.N. 
Laland, F.J. Odling-Smee, and M.W. Feldman, “The Evolutionary Consequences of Niche 
Construction: A Theoretical Investigation Using Two-locus Theory,” Journal of Evolutionary 
Biology 9 (1996): 293-316. For a discussion of how niche construction can be applied to the 
human social sciences (e.g., human niche construction, social learning, cultural inheritance, etc.), 
and a vigorous debate about that approach, see Kevin N. Laland, John Odling-Smee, and Marcus 
W. Feldman, and Commentators, “Niche Construction, Biological Evolution, and Cultural 
Change,” Behavioral and Brain Sciences 23 (2000): 131-175. 
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disease. There was a lag of several decades, for instance, between the rise of coronary disease 
and decisions by physicians and health officials to commit substantial resources against it. New 
disease concepts (e.g., atherosclerosis, coronary thrombosis), new technologies (e.g., the 
electrocardiogram), and new specialties (e.g., cardiology) all converged between the 1920s and 
1950s to open the therapeutic niche for coronary artery disease. 
 Theories of niche construction suggest that a therapeutic niche will be altered by the 
treatments that attempt to fill it. Antibiotics have changed their niche by triggering the 
emergence (evolution) of antibiotic resistant bacteria.50 Chris Feudtner has described the 
transformation (or niche construction) of diabetes.51 Before insulin, diabetes was an acute 
disease, with patients wasting away and then dying from ketoacidosis and hyperglycemic coma. 
After insulin, diabetes became a chronic disease, with patients developing diabetic retinopathy, 
nephropathy, neuropathy, and vascular disease. Each new complication opened a new therapeutic 
niche. The success of bypass surgery in the 1970s inspired cardiologists to develop angioplasty, 
which has now displaced bypass surgery from much of its niche. The complications of 
angioplasty, including restenosis and stent thrombosis, have created secondary niches, for 
platelet inhibitors and antiproliferative agents, that could not have been imagined in the 1950s. 
Used with attention to the subtleties that have been developed by evolutionary biologists, niche 
theory can be a valuable tool for historians of medicine. 
 
Fitness 
                                            
50 Robert Bud, Penicillin: Triumph and Tragedy (New York: Oxford University Press, 2007); 
Scott Podolsky, The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational 
Therapeutics (Baltimore: Johns Hopkins University Press, 2014). 
51 Chris Feudtner, Bittersweet: Diabetes, Insulin, and the Transformation of Illness (Chapel Hill: 
University of North Carolina Press, 2003). 
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 When doctors and patients think about therapeutics, they often focus on the most 
fundamental outcome: did the treatment work? This can be surprisingly difficult to determine. 
Outcome can be assessed from the perspective of the physician or the patient; by changes in 
symptoms, laboratory values, imaging studies, or life expectancy; after short, medium, or long 
intervals; and with case series, cohort studies, randomized trials, and meta-analyses. Historians 
have also been extremely interested in efficacy. As Rosenberg explored in his classic essay on 
therapeutic revolutions, and revisits in the next chapter, one of the most interesting puzzles has 
been understanding how and why assessment of efficacy changes over time. Bloodletting, now 
dismissed by biomedical scientists, was popular in western medicine for over two thousand 
years. It must have worked. The crucial challenge is to understand what work it did.52 
 The concept of efficacy has productive parallels with the concept of fitness. Darwin used 
“fit” and “fitted” throughout Origin, but it was only in the 1866 edition, influenced by Alfred 
Russel Wallace and Herbert Spencer, that he began to use “survival of the fittest.”53 Population 
geneticists have defined fitness as differential reproductive success, something that is not an 
absolute attribute of an organism but a measure of its success in a particular environment. Since 
reproductive success is sometimes random (e.g., an extremely “fit” organism could die in an 
accident), biologists have developed a “propensity” interpretation of fitness that distinguishes 
potential and realized fitness.54 
 It takes some tinkering to adapt evolutionary concepts of fitness to history of medicine. 
Treatments do not reproduce in any biological sense. Success is determined instead by the 
beneficial effect of a treatment on patients and the perception of that effect among physicians 
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and patients. However, at an abstract level, fitness can do useful work for historians. First, it 
actually is possible to think of fitness in terms of a treatment’s ability to generate progeny.55 As 
physicians work to improve treatments, whether pharmacological or procedural, they produce 
derivatives. Penicillin gave rise to methicillin, ampicillin, amoxicillin, and many other 
antibiotics. The first ß-blockers produced derivatives that diversified and filled other niches. 
Balloon angioplasty has inspired an ever-growing lineage of catheter-based interventions. If 
success at producing derivatives yields one with higher clinical efficacy, then the parent therapy 
dies out -- a victim of its own reproductive success. Second, it is possible to think of therapeutic 
fitness in terms of a treatment’s ability to expand a therapeutic niche. While sildenafil can 
produce erections, what really made it successful was its ability, through marketing, to transform 
the embarrassing problem of impotence into the profitable diagnosis of erectile dysfunction. In a 
similar way, it is possible for treatments to achieve success by creating sub-niches (segmenting 
the market?) for a series of treatments. The niche of hypertension now has space not just for one 
fittest antihypertensive, but for many fit diuretics, ß-blockers, and more. 
 The distinction between potential and realized fitness is useful as well. Doctors often 
think about both the optimal outcomes that can be achieved with a treatment and those realized 
in actual clinical practice. In this respect, randomized clinical trails measure potential fitness, 
while realized fitness is experienced by patients in routine clinical practice -- this is the 
distinction between efficacy and effectiveness. The problem of non-compliance fits in here as 
well, as one of the many barriers that stands between potential and realized fitness.56 Does a 
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treatment work? That cannot be answered simply, just as a biologist cannot say whether or not an 
organism is fit. Like biologists who assess fitness in the context of a specific niche, physicians 
and historians must assess efficacy in the context of the problem being treated, the outcomes 
most valued by the patients and doctors, and the ability of the health care system to deliver the 
treatment. 
 
Competition 
 Competition, one domain in which differential fitness reveals itself, has come to be seen 
as nearly synonymous with natural selection. It plays a key role in evolutionary theory. 
Biologists define it specifically as “the simultaneous reliance of two individuals, or two species, 
on an essential resource that is in limited supply.”57 What is the limited resource in medicine? 
There are many possibilities. Illness episodes generate the need for treatment (and the 
opportunity for reimbursement). Patients host illness episodes. Health care resources are 
deployed to treat them. Competition for episodes, patients, and resources takes place between 
different treatments (e.g., medications or surgery for coronary disease), providers (e.g., 
cardiologists, cardiac surgeons, nutritionists), institutions (e.g., from neighborhood clinics to 
national referral centers), and insurers. While overt competition was once considered unseemly 
in medicine, it is now routine, and billions of dollars are spent each year advertising to gain 
advantage. Each of these aspects of competition offers a productive target for historical analysis. 
 What determines the outcome of competition? Success in medicine is fickle. The best 
treatments, doctors, or health care systems do not necessarily outcompete the others. Doctors 
have sought to adjudicate competition between treatments with randomized clinical trials, but 
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there have been many obstacles to trials’ power.58 Success can come from better efficacy or from 
fewer side effects. Selective serotonin reuptake inhibitors, for instance, displaced tricyclic 
antidepressants not because of superior efficacy but because of increased safety (especially in 
overdose). Marketing campaigns have pushed many blockbusters to prominence even when 
those blockbusters had no significant advantage over existing treatments.59 Sometimes the 
cultural meanings of diseases and their treatments matter most. Anne Pollock has shown how 
racial dynamics have influenced the popularity of treatments for hypertension (e.g., guidelines 
once recommended diuretics for black patients and ACE inhibitors for white patients) and heart 
failure (e.g., the approval of BiDil for patients who self-identify as black).60 The fittest might 
survive, but there are many ways for a treatment to be fit. 
 
The Red Queen Hypothesis 
 In classic Darwinian theory, organisms struggle to adapt themselves to their environment. 
Biologists now recognize that niches change constantly over time, a result of both environmental 
change and shifting competitive landscapes as other species come and go. This has important 
consequences for adaptation and natural selection: organisms must adapt to something that is 
constantly changing. Invoking a scene from Lewis Carroll’s Through the Looking-Glass, 
evolutionary theorist Leigh van Valen in 1973 named this the Red Queen hypothesis.61 As the 
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Red Queen told Alice, in her world “it takes all the running you can do, to keep in the same 
place.”62 In biological terms, organisms might evolve constantly just to maintain a stable level of 
fitness in the changing environment. Subsequent theorists have introduced variants. One, 
restricting the Red Queen hypothesis to competitive interactions between species, coined a new 
phenomenon, the Court Jester effect, to analyze efforts by organisms to track random changes in 
their physical environments.63 As a 2009 article explained, the “Red Queen model stems from 
Darwin, who viewed evolution as primarily a balance of biotic pressures, most notably 
competition.” The Court Jester model, in contrast, argues “that evolution, speciation, and 
extinction rarely happen except in response to unpredictable changes in the physical 
environment, recalling the capricious behavior of the licensed fool of Medieval times.”64 
 The challenge of adapting to a changing niche provides a powerful intuitive model for 
understanding the fundamental task of medicine and public health: to provide relief from the 
diseases that afflict human populations. Physicians and public health officials seek to define and 
then eclipse the burden of disease.65 The problem is that the burden of disease is never static. It 
changes constantly in response to changing physical and social environments, the evolution of 
pathogenic micro-organisms, the advent of new and dangerous technologies (e.g., cars, 
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cigarettes), or the impact of decisive medical interventions (e.g., smallpox vaccination). 
Physicians and public health officials must struggle to keep up. Since innovation takes time, 
evolving medical therapies inevitably lag behind the changing burden of disease. 
 Physicians and medical researchers, for instance, set out to master bacterial disease in the 
1880s. They studied patients, identified causative micro-organisms, and then sought “magic 
bullets” that could cure the diseases, from immunizations and serotherapies early in the twentieth 
century to the “antibiotic revolution” in the 1950s analyzed in this volume by Scott Podolsky and 
Anne Kveim Lie. By that point, however, the burden of disease in the United States and other 
developed economies had shifted: cardiovascular disease and cancer had displaced infections as 
the leading causes of death.66 Medical scientists took on these new challenges, supported by 
major investments in health care and research (e.g., the National Cancer Institute, the National 
Heart Institute). By the early 2000s physicians could celebrate dramatic successes against 
coronary artery disease (e.g., diuretics, ß-blockers, ACE inhibitors, statins, bypass surgery, 
angioplasty, anti-smoking campaigns, etc.) and cancer (e.g., cytotoxic chemotherapy, surgery, 
radiation therapy, targeted chemotherapies, etc.). The burden of disease, however, continues to 
shift, with neuropsychiatric conditions rising to new prominence (e.g., depression, dementias, 
substance use). Medical science and public health will hopefully produce solutions to these 
conditions, but the burden of disease will surely shift once again. 
 A second Red Queen effect has played out in parallel. Just as medical and public health 
practitioners and institutions struggled to keep pace with the changing burden of disease, clinical 
researchers have struggled to produce knowledge of therapeutic efficacy that keeps up with 
changing therapeutic practice. Definitive assessment of efficacy often requires long-term follow 
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up (e.g., three- or five-year survival). Clinical trials that assess such outcomes necessarily last 
many years: design, patient recruitment, implementation, follow up, and analysis all take 
significant time to complete. Trial outcomes often are not published until five to ten years after 
the design of the intervention protocol. Are the ensuing results relevant? It depends on 
assumptions about therapeutic evolution. If you believe, as many patients and doctors do, that 
treatments improve over time, then a trial’s results are undermined before they are even 
published. They reflect treatment as it existed ten years previously, an ancestral -- and more 
primitive -- form. 
 Consider the trials of coronary angioplasty. By the mid-1990s angioplasty had become a 
routine treatment for stable coronary disease even though there was little convincing evidence 
that it added value beyond optimal medical therapy. To produce decisive data, investigators from 
fifty sites designed the COURAGE trial to detect any incremental benefits provided by 
angioplasty.67 They enrolled 2287 patients between June 1999 and January 2004 and followed 
them through June 2006. Over a mean follow-up of 4.6 years, they found no significant 
differences in rates of death, heart attacks, or hospitalization for acute coronary syndromes. This 
study, published in March 2007 in the New England Journal of Medicine, was trumpeted in the 
press as a “blockbuster.” Shares of Boston Scientific, a leading stent manufacturer, fell and stent 
use dropped 10% within a month.68 Supporters of angioplasty rushed to the procedure’s defense. 
Since enrollment began in 1999, most COURAGE patients (97.7%) received bare metal stents. 
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In 2003, however, drug-eluting stents designed to prevent restenosis became available in the 
United States.69 Most cardiologists assumed that the new stents would outperform the old stents. 
As a result, “one could very reasonably hypothesize” that the outcomes of COURAGE would 
have been better had drug-eluting stents been used.70 And since drug-eluting stents had already 
come to dominate the marketplace, critics argued that COURAGE was obsolete on arrival. Its 
negative results need not diminish enthusiasm for the variants in current use. The evidence base, 
always running, can never catch up. 
 
Extinction 
 Most species that have ever existed have gone extinct.71 The same holds true in medicine. 
Many once popular therapies have vanished, with competition probably the most common cause 
of extinction. When chlorpromazine appeared in the mid 1950s, lobotomy was made “redundant” 
and went extinct.72 Chlorpromazine and other “typical” antipsychotics have since been driven 
close to extinction by newer (and heavily marketed) “atypical” antipsychotics. Sometimes a new 
competitor wipes out whole lineages. In the 1960s surgeons utilized many different approaches 
to coronary revascularization; nearly all of them disappeared with the emergence of bypass 
surgery in 1968.73 Changes in the niche can be important as well. As Condrau and Kehr describe 
in this volume, the decline of tuberculosis in the United States and Europe eliminated the need 
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for rest cures, sanatoria, thoracoplasty, and a host of other once-popular interventions. Smallpox 
vaccine sowed the seeds of its own demise by eradicating its own niche. If enough individuals 
find ways to control coronary disease through lifestyle and prevention, then bypass surgery and 
countless other treatments might disappear as well. 
 While studies of the extinction of specific treatments can be productive, historians can 
also follow the lead of evolutionary biology and look at broader patterns in therapeutic evolution. 
How have rates of speciation and extinction changed over time? Have periods of massive 
therapeutic proliferation (e.g., the “antibiotic revolution” as Burghess Shale?) typically been 
followed by periods of therapeutic mass extinction, as competition winnows out unfit therapies? 
It is necessary to organize the data of therapeutic evolution before it is possible to see its 
patterns. 
 
Taxonomy 
 Scholars in many fields, confronted with large data sets, have sought ways to organize 
them. In natural history this became the science of taxonomy. Taxonomy is not simply about 
description and sorting. Instead, it requires that arguments be made about affinity: which things 
are most closely related? Taxonomists have long debated the merits of taxonomies based on 
morphology or genealogy.74 This distinction is relevant in medicine as well. Doctors can classify 
diseases according to organ system or etiology, but ambiguities always persist. Does it make 
sense to define a category of pneumonia, regardless of whether it is caused by staph or strep, or 
do strep infections form the “natural kind” regardless of whether they strike lung, throat, or 
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skin?75 The situation is different for classifying therapies. Many writers, especially in review 
articles and textbooks, offer typological classifications of medications. Psychiatric drugs can be 
divided into antidepressants, antipsychotics, mood stabilizers, or anxiolytics. Antihypertensives 
can be divided into diuretics, vasodilators, ß-blockers, calcium channel blockers, ACE inhibitors, 
angiotensin receptor blockers, and presumably others yet to come. But treatments, like species, 
have evolved over time. This makes it possible for physicians and historians to produce 
therapeutic genealogies. The different ways of classifying raise important questions for historian 
of medicine. 
 First, medical taxonomies, like biological taxonomies, changed over time as medical 
knowledge changed and as doctors made new claims about affinity. Taxonomies of fever 
changed with the rise of germ theory.76 The classification of substance use has swung between 
vice and disease.77 The shifts can be abrupt, especially when a bureaucratic power imposes a new 
taxonomic order. In 1892, for instance, the Department of the Interior issued new rules for 
physicians who worked on Indian reservations.78 Consumption, which had been a constitutional 
disease in 1891, along with cancer, anemia, dropsy, and rheumatism, became tuberculosis, an 
infectious disease, like chicken-pox, diphtheria, measles, and influenza. Theorists of cartography 
have long argued that maps are not simply descriptions of geographic space. Instead, maps are 
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arguments, the product of strategic decisions about what data to represent and how to represent 
them.79 Taxonomies function similarly, making arguments about the affinity, etiology, or 
genealogy of diseases or therapeutics. 
 Second, superimposing genealogy on top of typological taxonomy reveals important 
boundary crossings in the history of therapeutics. Walter Sneader, for instance, has used 
evolutionary taxonomy to organize knowledge of pharmacology and trace its history in his 
“genealogical approach to drug discovery.”80 Some lineages develop methodically, with all 
progeny staying within the same therapeutic class as the prototype. Penicillin gave rise to many 
generations of antibiotics, selected (designed) to be long acting (e.g., procaine penicillin), 
resistant to penicillinases (e.g., methicillin), broad spectrum (e.g., ampicillin), or orally absorbed 
(e.g., amoxicillin).81 Other lineages are full of surprises. Consider the descendants of 
epinephrine. Analogs (i.e., adrenergic agonists, e.g., albuterol) remain a mainstay of asthma 
therapy. Antagonists (i.e., ß-blockers, e.g., propranolol), developed to protect the heart against 
adrenaline surges, proved useful not just for coronary artery disease but also hypertension. Some 
researchers developed derivatives with less neurotoxicity (e.g., atenolol) to make hypertension 
regimens more tolerable. Other researchers, intrigued by the vivid dreams produced by lipophilic 
ß-blockers, sought more psychoactive derivatives, a pursuit that yielded the serotonin and 
norepinephrine reuptake inhibitors that have transformed the treatment of depression.82 Many 
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other pharmaceutical lineages have jumped across functional classes. Antimalarials produced 
antihistamines and then antipsychotics.83 B-vitamins gave rise to drugs for tuberculosis (e.g., 
isoniazid) and depression (e.g., iproniazid and other monoamine oxidase inhibitors).84 
 The ways in which drug lineages transgress therapeutic class reveal not just the 
complexity of pharmacology (e.g., the subtlety of drug-receptor interactions), but also the 
important role of serendipity. Researchers who develop derivatives for one purpose often 
stumble across drugs useful for another purpose. This resembles the processes of exaptation 
described by biologists. Just as feathers likely evolved as insulation before they enabled flight, 
drug derivatives often find unanticipated applications. 
 Similar processes take place in surgery. Between 1920 and 1970 surgeons developed a 
bewildering diversity of surgical procedures to treat coronary artery disease. Sometimes a 
lineage preserved its function even as its form changed completely. For instance, techniques to 
slow the body’s metabolism by reducing thyroid function evolved from surgical resection of the 
thyroid in the 1930s to destruction of thyroid tissue with radioactive iodine in the 1950s. 
Exaptation has been common, with techniques developed in one area of surgery (e.g., saphenous 
vein interposition grafts to repair renal artery stenosis) finding application elsewhere (e.g., 
coronary artery disease). Once coronary artery bypass surgery achieved a foothold in its niche, it 
underwent adaptive radiation and gave rise to many variants, including recent attempts at 
minimally invasive procedures. The adaptive radiation of the angioplasty lineage has been even 
more dramatic (and profitable), with balloon techniques giving rise to atherectomy, laser 
ablation, stents, and many others. 
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 Questions of lineage and taxonomy often become relevant for policy. How much change 
can accumulate in a therapeutic lineage while preserving functional identity? When is new 
evidence and regulatory oversight required to ensure that the treatment still works as its 
predecessors did? According to the 1976 Medical Device Amendment, a new device can be 
approved expeditiously if it is substantially equivalent to an existing device -- the 510(k) process. 
This policy has been exploited by device manufacturers. One analysis of artificial hip implants 
included a branching tree diagram that traced the genealogical relations between 63 current 
implants and their ancestral forms.85 The authors argued that, despite serial claims of substantial 
equivalence, significant changes had accumulated in the lineage over its many generations, and 
these required new regulatory oversight. At what point has speciation, and thus the need for 
renewed regulatory scrutiny, taken place? It is not always clear. Generic drugs raise similar 
questions. What kinds of similarity produce sufficient taxonomic affinity such that a generic drug 
can be assumed to be therapeutically -- and bureaucratically -- interchangeable with the parent 
drug? As Jeremy Greene has shown, distinctions are made not just on the structure of the active 
ingredient, but also on the binders and fillers that might affect bioequivalence, and the shapes, 
colors, and tastes that might affect pill-taking behavior.86 
 
Island Biogeography 
 Taxonomies raise questions not just about change over time, but also about the 
distribution of diversity over space. For instance, evolutionary theorists have studied how 
variation emerges in geographically isolated populations ever since Darwin’s famous voyage to 
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the Galapagos Islands. As local varieties emerge, the isolated locales become sites for speciation. 
These intuitions were formalized in 1967 by Robert MacArthur and E. O. Wilson in their 
analyses of how so many species can exist on islands. Subsequent work has examined the ways 
in which islands become sources of novelty (i.e., speciation). Sometimes new species form when 
an existing species expands to occupy an open niche, subsequently splitting into two. At other 
times new species form when a geographic or behavioral barrier divides the group into two 
diversifying lineages.87 The combination of isolation and small population size contributes to the 
rapid pace of change. 
 Medical geographers and historians have long wondered about the distribution of disease, 
especially the dynamics that influence the emergence of new pathogens in isolated regions and 
their potential dissemination.88 The island biogeography of medical practice deserves similar 
attention. Jeremy Greene, in this volume, explores the significance of geographic variations in 
drug availability and pricing. A distinct literature exists about practice variation in surgery. From 
J. Alison Glover’s 1938 description of a 27-fold disparity in tonsillectomy rates across London 
neighborhoods to the colorful maps of the Dartmouth Atlas of Health Care today, physicians 
have mapped striking disparities in medical practice between hospitals, cities, regions, and 
nations.89 As John Wennberg and Alan Gittelsohn concluded in 1975, geographic variations in 
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medical practice “are a rule for which there is yet no exception.”90 If practice variation simply 
reflected variation in the underlying burden of disease (i.e., if there were a perfect correlation 
between the biogeography of disease and the biogeography of medical practice), then it would 
not be interesting. However, an extensive body of research by physicians has concluded that 
much of the variation appears to be “unwarranted,” reflecting not the application of evidence 
based medicine to local burdens of disease, but instead the influence of physician supply, 
reimbursement practices, financial conflicts of interest, medical uncertainty, idiosyncratic 
differences in physicians’ beliefs and practices, and myriad other influences on medical decision 
making. Health policy experts have long seen the existence of unwarranted variation as a 
problem. As Frederick Robbins, president of the Institute of Medicine, wrote in 1983, “’it looks 
bad, and it looks bad because it is bad. It is not an appropriate way for a profession to behave.’”91 
Physicians and analysts have worked to identify the causes of unwarranted variation and purge it 
from medicine. 
 Historians can offer different perspectives. The first is epistemological: why did 
physicians become concerned about geographic variations when they did? The variations have 
existed for centuries.92 When Glover identified them in 1938, his work triggered no interest in 
the problem. It was only in the 1960s and 1970s that the problem received attention in the United 
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States, in the setting of two developments: concern about the skyrocketing costs of health care 
and the emergence of evidence-based medicine.93 It is not difficult to understand why 
documentation of unwarranted variation has been an affront to the aspirations of evidence-based 
medicine. Advocates of this movement have sought to discipline medical practice and bring it 
into conformity with the dictates of clinical data. Historians can contribute to this endeavor, for 
instance by helping to chart the forces that pull medical practice out of alignment with evidence-
based medicine. Or they can choose to complicate the endeavor. Is it plausible that medicine 
could ever be a fully rational science, isolated from social, economic, and political influences? 
Few historians think this likely. Their analyses of historical contingency and the importance of 
local context can reveal the inevitable limits of evidence-based medicine. 
 The second perspective turns the problem of geographic variation into an opportunity. 
Historians, informed by biologists’ theories of island biogeography, could argue that local 
variation in medical practice is actually a good thing. Isolation and local variation produced new 
traits and species in organismic evolution. Something similar has played out in the history of 
medicine. Different physicians and health care institutions have developed different approaches 
to particular clinical problems. In the ideal situation, doctors share and compare practices and 
contribute to medical progress. Aseptic surgery first developed in a particular late nineteenth 
century German surgical culture and then spread widely.94 Directly observed therapy, developed 
to improve compliance with outpatient tuberculosis regimens in Madras in the 1950s, became a 
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mainstay for treatment of many diseases in many places.95 But these are the best case scenarios. 
There has never been an efficient system that evaluates different local practices and determines if 
one really is better than another. This is, of course, the nature of island biogeography. The 
barriers to exchange -- physical, cultural, or otherwise -- that foster local variation and 
innovation can impede their dissemination. 
 
Morphospace 
 One last concept is particularly thought provoking. As Hutchinson formulated his niche 
theory in 1957, he realized that a niche was defined not just by two or three features of the 
environment and organism, but by innumerable factors. It was not simply a three-dimensional 
space, like an architectural niche, but an “n-dimensional hypervolume ... every point in which 
corresponds to a state of the environment which would permit the species S1 to exist 
indefinitely.”96 This concept of the niche as a multidimensional hypervolume inspired a 
secondary idea, that of an n-dimensional trait space. As Steven Jay Gould wrote in 1991, 
“morphospace” represents the “full range of the abstract (and richly multivariate) space into 
which all organisms may fit.”97 Any creature, real or imagined, occupies just a small patch. 
Conceptualized this way, morphospace presented Gould and his fellow biologists with a 
challenge: “we need to measure density, range, clumping, and a host of other properties that 
                                            
95 Ronald Bayer and David Wilkinson, “Directly Observed Therapy for Tuberculosis: History of 
an Idea,” Lancet 345 (1995): 1545-1548. 
96 G. Evelynn Hutchinson, “Concluding Remarks,” Cold Spring Harbor Symposium on 
Quantitative Biology 22 (1957): 415-427. 
97 Stephen Jay Gould, “The Disparity of the Burgess Shale Arthropod Fauna and the Limits of 
Cladistic Analysis: Why We Must Strive to Quantify Morphospace,” Paleobiology 17 (1991): 
411-423, on p. 420. 
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determine differential filling of this totality; and we must be able to assess the variation in this 
differential filling through time.”98 
 Morphospace provides evolutionary biologists with a teachable moment about 
contingency and developmental constraints. Large tracts of morphospace, once occupied, are 
now empty (e.g., trilobites, dinosaurs), the contingent result of meteor strikes and other causes of 
mass extinctions. But most morphospace has never been occupied. If you imagine every possible 
form a living creature could take (photosynthetic elephants! winged horses! dragons!), you 
quickly realize that most of these things ever existed. There are no six-limbed vertebrates. There 
are no talking horses. Instead, you find isolated clusters of creatures, with vertebrates in one 
region, crustaceans in another, trees someplace else, and an enormous -- but still finite -- cloud of 
bacteria. The lesson here is about constraint. Evolution works with a limited substrate: extant 
species. Since embryological development imposes constraints on how much one generation can 
vary from its parents, new species cluster near existing species and only slowly move into 
unfilled space. There is a wide gulf between realized and potential creatures. 
 Morphospace provides historians of medicine with two useful thought experiments. 
Thinking about disease space (pathospace?) is simple enough at first: it is the task of nosology 
and disease taxonomy. However, as you define the possible axes of disease space to capture 
every type of disease that does exist and begin to wonder about every type of disease that might 
exist, it quickly becomes an exercise in morbid imagination, one pursued enthusiastically in 
horror films and science fiction. Zombie viruses are simply the most recent in a long line of 
appalling imagined diseases. Fiction aside, disease space raises an important question about the 
                                            
98 Gould, “The Disparity”: 420. Gould admitted that this task was “dauntingly difficult” (420) at 
best, and possibly “logically intractable” (421). See also Benjamin Blonder, Christine Lamanna, 
Cyrille Violle, and Brian J. Enquist, “The n-Dimensional Hypervolume,” Global Ecology and 
Biogeography 23 (2014): 595-609, on p. 603. 
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social determinants of disease: to what extent do we control which swathes of disease space are 
occupied? Many diseases exist now because of decisions people have made about how to 
structure their societies, from smoking-related illnesses to obesity, substance abuse, lead 
poisoning, or car accidents. Our hunter-gatherer ancestors were presumably spared these 
diseases. What about our descendants? It is possible to imagine a world free of lung cancer, 
bronchitis, and emphysema. If tobacco use ceased, those diseases would almost certainly slip 
back into the domain of diseases that could be imagined, but do not actually exist. 
 The thought experiment is even more productive with therapeutics. Imagine an n-
dimensional trait space for medical interventions, not just a pharmacospace or a surgerispace, but 
a therapospace, a remedispace -- an iatrospace. The dimensions would allow the full range of 
conceivable interventions (pharmaceutical, surgical, interactional, natural, synthetic, magical, 
religious, specific, universal, etc.) for every possible disease. Within this iatrospace could be 
found the actual treatments that do exist, abandoned treatments that once were popular, and ideal 
future treatments towards which medical research strives: magic bullets for cancer, drugs that 
reverse dementia, a vaccine for HIV, or an electromagnetic wand that dispels depression. As 
patients and doctors know too well, existing treatments occupy but a tiny fraction of potential 
iatrospace. The history of these shortcomings is, in part, a history of constraint. There are limits 
on what surgery can accomplish, and even though thousands of biologically-active compounds 
have been tested, it has not been possible to find a perfect drug for every clinical problem. 
Furthermore, just as natural selection can only work with existing species, doctors largely use 
existing treatments to produce subsequent, incremental derivatives. 
 But unlike in biology, physicians can influence how iatrospace gets filled. They can 
consciously imagine the space of potential therapeutics, recognize gaps that exist, and work to 
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fill them. Rational drug design, one of the many promissory sciences of contemporary 
biomedicine, demonstrates this well. As doctors characterize the mechanisms of disease in ever 
increasing detail and improve the resolution of their map of the n-dimensional volume of disease 
space, they identify new destinations in iatrospace. Advances in cancer science allowed doctors 
to move beyond surgical resection to cytotoxic chemotherapy, radiation, and now targeted kinase 
inhibitors. While there have been a few dramatic successes, many promising areas of iatrospace 
have not been reached. This model can help understand therapeutic failure as well. Psychiatrists, 
for instance, do not yet have a detailed enough map of psychiatric disease space to identify 
specific targets for therapeutic intervention. It might even be possible to construct a taxonomy of 
medical practice according to barriers to a total eclipse of different segments of the burden of 
disease. In some areas, as in psychiatry, the problem is our understanding of disease space. In 
others, as is increasingly the case in oncology or infectious disease, the challenge is finding an 
actual molecule that performs a well-characterized function within iatrospace. 
 These abstractions of n-dimensional hypervolumes, of disease space or iatrospace, bring 
together different threads of evolutionary theory. They provide domains in which not only 
niches, but also taxonomy, fitness, extinction, adaptive radiation, and many others play out. 
While evolutionary biology remains a distant analogy for the development of medical theory and 
practice, the theories of evolutionary biology can inspire productive theorizing within history of 
medicine. 
 
The Problem of Progress 
 Historians of medicine can adapt theories and metaphors from evolutionary biology and 
develop new modes of description, new arguments about causation, and new perspectives on the 
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dynamics of change over time. But historians must think carefully if they do so. Is the analogy 
specific enough for evolutionary theory to add real value when applied to non-biological 
systems? Can our understanding of efficacy really be enhanced by insights about fitness or the 
therapeutic niche? The rhetoric of evolution, like that of revolution, requires careful handling by 
historians of medicine. It is important to think not just about the potential creative insights it 
offers, but also about the potential downsides of evolutionary concepts. The most relevant 
dilemma with evolution for historians of medicine, as with revolution, is the problem of 
progress. 
 Progress has long been associated with the varied meanings of evolution. “Progress” 
entered English from Latin in the fifteenth century, to mean a step forward, as on a march or 
journey. The movement was not necessarily positive, as seen in the usage (which continues) of 
“the progress of a disease.”99 Through an association with “evolution,” however, “progress” 
gradually gained the meaning of movement from worse to better, first as “an inherent principle 
of development of higher forms,” and then more broadly to “an inherent process of social and 
historical improvement.”100 Most eighteenth and nineteenth century writers saw progress in 
idealist terms, though some became increasingly concerned about the costs of progress. 
 The association of evolution with progress has long been a bugaboo for biologists.101 
Traditional evolutionary thought assumed that evolution brought progress, as seen in ubiquitous 
imagery of the great chain of being. It is true that there are creatures living today that are more 
complex than the most complex creatures two billion years ago, and it is unlikely that anyone 
living now would trade their human existence for that of a unicellular critter from eons past. 
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Nonetheless, the scientific literature now takes a much more nuanced approach to progress. 
Phylogenetic lineages are full of dead ends. Some species lose functions over time (e.g., eyeless 
cave fish). A trait might satisfy a local selective pressure and proliferate, but decrease fitness in 
the long run (e.g., possibly the giant antlers of the Irish elk). Mass extinctions occurred 
repeatedly, with lineages vanishing sometimes for explicable causes and sometimes seemingly at 
random. At a global scale, evolution has actually maintained something of a status quo: if you 
plot complexity on the x-axis and the number of species achieving that level of complexity on 
the y-axis, the median organism on earth for billions of years has always been, and still remains, 
a bacterium.102 Nothing about natural selection or ecological dynamics as now understood 
necessitates progress. 
 Progress has been a similar problem in history of medicine, even among writers who 
would not self-identify as Whigs. Osler, Garrison, and many more recent historians have 
celebrated the progress of medicine. When doctors talk about treatments, practices, and 
institutions evolving, a sense of progress is part of this discourse. The assumption is that the new 
is better than the old, with evolution producing ever better understandings and interventions. In 
the 1960s, however, some historians of medicine turned away from these positivist assumptions 
and towards meta-narratives of relativism, skepticism, and critique. But progress is hard to set 
aside. Just as no one would want to live the life of an archaic bacterium, there are few who 
would choose to give up modern medical technology and live with medicine as it existed even 
50, let alone 100 or 200 years ago. Historians have tried to find a balance by acknowledging the 
possibility of progress without accepting its inevitability. 
                                            
102 Variation around this mean, however, has increased. This accounts for the appearance of 
more complex life forms over time. 
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 Historians of medicine who are attuned to assumptions of evolutionary progress can offer 
perspective on progress in the medical literature. Physicians often deploy several different 
rhetorics of progress to generate faith and enthusiasm in new therapies -- and to discount the 
need for scholarly or regulatory scrutiny. In some cases they accentuate the merits of a break 
from the past. For instance, when coronary artery bypass grafting launched in the late 1960s, it 
was the latest in a long series of surgical attempts to treat coronary artery disease. Since prior 
techniques had ended in disillusionment, skeptics often assumed that the new operation would be 
no different. They demanded that bypass surgery be subjected to rigorous trials. Surgeons did not 
deny this history; rather, they denied its relevance. They argued that past surgical treatments had 
failed because they had relied on inadequate diagnostic technology. The advent of coronary 
angiography in the 1960s, however, allowed surgeons to visualize the coronary arteries before 
making a decision about surgical intervention, a “leap forward in our ability to read coronary 
disease that can be fairly likened to the impact of the invention of the printing press on the 
written word.”103 This diagnostic revolution ruptured any kind of historical continuity. As 
surgeon Donald Effler explained, “Whatever surgical efforts were expended before are of 
historical interest only, and it does little good to dwell on past failures.”104 
 In other cases doctors place their emphasis on gradual progress. A physician might 
develop a variant on an existing treatment and make a claim of incremental, evolutionary 
progress: the new is similar enough to the old, but improved, so that it should be trusted at the 
outset. This strategy allows doctors to tweak the dose of an approved regimen or adjust an 
operation in an attempt to make it safer, quicker, cheaper, or more effective. As long as everyone 
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assumes that the tweak is positive, then there is no need for new clinical trials or regulatory 
review. For instance, just as the Food and Drug Administration allows expedited approval if a 
new device is substantially equivalent to an existing device, it also grants the benefit of the doubt 
if the device involves “incremental innovations” of an existing device.105 Is this wise? It depends 
on assumptions of progress. Device manufacturers argue that if the first device was safe and 
effective, then their slightly improved device should be safe and effective as well, hopefully 
more so. This intuition has worked well in many instances: incremental change has allowed for 
the safe flourishing of numerous medical devices and operative procedures. But device 
companies have now spawned so many generations of derivatives that some new devices bear 
little resemblance to the distant ancestor on which their approval relied, and many have been 
approved without specific clinical evidence. Consider implantable devices used to control 
cardiac arrhythmias. Between 1979 and 2012, the Food and Drug Administration granted 77 
formal premarket approvals and an additional 5829 supplements, 37% of which involved a 
change in design.106 Several of these devices failed, a consequence of unfulfilled assumptions of 
progress. 
 The challenge for historians is to use the language and theories of evolution skillfully. 
Evolutionary language can certainly imbue historical writing with assumptions of progress, just 
as assumptions of progress still pervade popular understandings of organismic evolution. 
However, biologists have learned to disentangle evolution and progress and tell stories about the 
multiple possible outcomes of evolution. Historians should also be able to invoke medical 
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evolution (or revolution) and simultaneously subject the question of progress to the scrutiny it 
requires. 
 
Evolution or Revolution? 
 Physicians, patients, and historians share an interest in the dynamics of medical change. 
Physicians and patients want rapid progress. Historians want to understand the dynamics and 
causes of change (and, when they get sick, most hope that medical science has progressed!). The 
rhetoric of revolution holds much appeal, for physicians celebrating an innovation or for 
historians drawing attention to the importance of their object of study. A claim of revolution is a 
demand for attention. However, as Roy Porter warned, historians must take care not to be drawn 
into the drama and over-state the claim. The essays in this volume provide a nuanced view of the 
subtleties and stakes of revolutionary claims. What about the opposing metaphor, of evolution? 
The rhetoric of evolution also looks to progressive improvement, but with reassuring gradualism 
in place of frightening rupture. If revolutionary change satisfies those who are dissatisfied with 
existing practice and want something fundamentally new, then evolutionary change reassures 
those who want gradual improvement of existing practice. 
 Historians need not adjudicate whether evolution or revolution is better. Instead, they can 
make two important contributions. First, they can mine scholarship on revolution and evolution, 
whether from political science or biology, to develop tools to refine our understanding of the 
past. Porter defined strict standards for revolution (i.e., a self-conscious overthrow of an existing 
scientific orthodoxy) and used those to characterize purported scientific revolutions. Historians 
can adapt concepts of evolution to analyze and understand change over time. Second, they can 
attend closely to language and its connotations. Whether the model is evolution or revolution, 
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one core consequence seems to be the same: the expectation of a better future. However, there is 
nothing inherent in the theory of either evolution or revolution that ensures progress. In fact, 
there is much in the dynamics of evolution, whether of niches, competition, Red Queen effects, 
or morphospace that argues against progress. While progress is a possible outcome of organismic 
evolution, it is not an inevitable one. When it takes place, it requires specific explanation. The 
same holds true for medicine and its history. 
 
